BUZZ - Driven by active trading, the Australian Securities Exchange (ASX) is on track for its best week in two months
路透社2026/10/09 00:56October 9 – The stock price of ASX ASX.AX, the operator of the Australian Securities Exchange, has risen more than 3.8% so far this week, on track for its best weekly performance since early August. On Thursday, Citi raised its annual earnings per share (EPS) forecast for ASX by 2%, citing continued strong trading activity. On Friday, the stock was up as much as 0.3% to 60.79 AUD. Citi also holds a positive view of ASX’s new CEO, Anthony Attia, agreeing with his approach of bringing in external talent and modernizing technology. Including the latest gain, the stock is up 18% year-to-date. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. Since automated translations may contain errors or lack context, Reuters does not guarantee the accuracy of the translation. The automated translation is provided solely for the convenience of readers, and Reuters accepts no liability for any damage or loss arising from the use of the automated translation.)
October 9 - ** The share price of Australian Securities Exchange operator ASX ASX.AX has risen more than 3.8% so far this week, on track for its best weekly performance since early August
** On Thursday, Citi (link) raised its annual earnings per share (EPS) forecast for ASX by 2%, citing continued strong trading activity
** On Friday, the stock was up as much as 0.3% at A$60.79
** Citi also takes a positive view of ASX’s new CEO Anthony Attia, agreeing with his focus on bringing in external talent and modernizing technology
** Including the latest gains, the stock is up 18% year to date
(To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translations may contain errors or lack the required context, Reuters does not guarantee the accuracy of the translated text. These translations are provided solely for the convenience of readers. Reuters accepts no responsibility for any harm or losses arising from the use of automated translation features.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Even with Eli Lilly's endorsement, TRex Bio (TRXB.US) struggles to enjoy a premium, as the issue price drops to the lower limit of $14.
Early-stage biotechnology company TRex Bio has priced its IPO at the lower end of the range at $14 per share, raising $116.7 million and achieving a market capitalization of $384 million. The company will be listed on Nasdaq on Friday, with Eli Lilly expressing interest in increasing its stake.
Small molecule biotechnology company Iambic Therapeutics (IAM.US) IPO priced at $15-17 per share, aiming to raise $150 millions.
Iambic Therapeutics plans to raise $150 millions by issuing 9.4 million shares, with an offering price range of $15 to $17 per share.
Pimco warns: 10-year US Treasury yield may hit 6%, for the first time since 2000
PIMCO's Chief Investment Officer stated that due to high oil prices intensifying inflation concerns and market unease over the growing U.S. public debt, the benchmark 10-year U.S. Treasury yield could rise to 6% for the first time since 2000.
Crypto prices
More
